Gilead Sciences (NASDAQ:GILD) Price Target Raised to $155.00

Gilead Sciences (NASDAQ:GILD) had its price objective upped by UBS Group from $145.00 to $155.00 in a research report released on Monday morning,Benzinga reports. UBS Group currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently weighed in on GILD. TD Cowen lifted their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $135.00 price target on shares of Gilead Sciences in a research report on Friday, October 31st. Daiwa Capital Markets upped their price target on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Finally, The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $135.36.

Gilead Sciences Trading Down 0.9%

NASDAQ:GILD opened at $139.72 on Monday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences has a 1-year low of $93.37 and a 1-year high of $141.71. The firm has a market capitalization of $173.35 billion, a price-to-earnings ratio of 21.66, a price-to-earnings-growth ratio of 0.74 and a beta of 0.33. The stock has a fifty day simple moving average of $124.76 and a 200 day simple moving average of $119.24.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the firm posted $2.02 earnings per share. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. Sell-side analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Buying and Selling

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total value of $6,590,411.10. Following the completion of the transaction, the executive vice president directly owned 43,676 shares in the company, valued at $5,365,596.60. This trade represents a 55.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. This trade represents a 20.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 247,397 shares of company stock worth $31,986,612 over the last three months. Company insiders own 0.27% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. GoalVest Advisory LLC grew its position in shares of Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Corundum Trust Company INC acquired a new stake in Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the second quarter worth about $27,000. Financial Consulate Inc. increased its position in Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 109 shares during the last quarter. Finally, Putney Financial Group LLC raised its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 94 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Phase‑3 Trodelvy combo beat Keytruda + chemo in a pivotal study, sparking a sharp rally and renewed bullish debate about Gilead’s oncology upside. Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial
• Positive Sentiment: Multiple analyst upgrades/price‑target raises (Citigroup to $156, Truist, BMO, UBS commentary) are reinforcing buy-side momentum and likely supporting higher valuations in the near term. Citigroup adjusts price target on Gilead Sciences to 156 from 140; maintains buy rating
• Neutral Sentiment: Gilead will report Q4 & full‑year 2025 results on Feb 10 — a clear near‑term catalyst that could amplify either the positive trial reaction or reveal operational headwinds. Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026
• Neutral Sentiment: News aggregator and investor‑attention pieces (Zacks, sector writeups) are boosting visibility but are not new fundamental information. Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
• Neutral Sentiment: Short‑interest data in the feed shows zero shares/NaN (likely a reporting artifact) — not a reliable signal for positioning or squeeze risk today.
• Negative Sentiment: CEO Daniel O’Day sold 115,640 shares (~$15.6M) in late January, reducing his holding ~17% — a notable insider sale that market participants may view as a short‑term negative or liquidity event. SEC filing: Form 4 — Daniel Patrick O’day sale

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.